An ORR of 63–67%, mPFS of 9.3–14·9 m, and overall survival benefits have been demonstrated in randomized trials of targeted therapy with BRAF/MEK inhibitors in metastatic melanoma [70,71]. Here, BRAF is linked to metastatic melanoma.